US Markets

Merck and Bayer's heart drug meets main goal of late-stage study

Credit: REUTERS/BRENDAN MCDERMID

Merck & Co Inc said on Monday an experimental treatment being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study.

Nov 18 (Reuters) - Merck & Co Inc <MRK.N said on Monday an experimental treatment being developed with Bayer AG BAYGn.DE for patients with worsening chronic heart failure met the main goal of a late-stage study.

The drug, vericiguat, reduced the risk of heart failure and hospitalization in patients with worsening chronic heart failure compared to placebo, when given in combination with available therapies for the condition, Merck said.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Samuel)

((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646 223 8780, outside the U.S. +91 80 6749 1692;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest US Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More